Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer Matters

Randomised control trial data support the use of stereotactic radiosurgery (SRS) in up to 4 brain metastases (BMs), with non-randomised prospective data complementing this for up to 10 BMs. There is debate in the neuro-oncology community as to the appropriateness of SRS in patients with >10 BMs....

Full description

Bibliographic Details
Main Authors: James de Boisanger, Martin Brewer, Matthew W. Fittall, Amina Tran, Karen Thomas, Sabine Dreibe, Antonia Creak, Francesca Solda, Jessica Konadu, Helen Taylor, Frank Saran, Liam Welsh, Nicola Rosenfelder
Format: Article
Language:English
Published: MDPI AG 2024-05-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/31/6/228